RT Journal Article
SR Electronic
T1 Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.12.21249713
DO 10.1101/2021.01.12.21249713
A1 Naushin, Salwa
A1 Sardana, Viren
A1 Ujjainiya, Rajat
A1 Bhatheja, Nitin
A1 Kutum, Rintu
A1 Bhaskar, Akash Kumar
A1 Pradhan, Shalini
A1 Prakash, Satyartha
A1 Khan, Raju
A1 Rawat, Birendra Singh
A1 Tallapaka, Karthik Bharadwaj
A1 Anumalla, Mahesh
A1 Chandak, Giriraj Ratan
A1 Lahiri, Amit
A1 Kar, Susanta
A1 Mulay, Shrikant Ramesh
A1 Mugale, Madhav Nilakanth
A1 Srivastava, Mrigank
A1 Khan, Shaziya
A1 Srivastava, Anjali
A1 Tomar, Bhawna
A1 Veerapandian, Murugan
A1 Venkatachalam, Ganesh
A1 Vijayakumar, Selvamani Raja
A1 Agarwal, Ajay
A1 Gupta, Dinesh
A1 Halami, Prakash M
A1 Peddha, Muthukumar Serva
A1 Sundaram, Gopinath M
A1 Veeranna, Ravindra P
A1 Pal, Anirban
A1 Agarwal, Vinay Kumar
A1 Maurya, Anil Ku
A1 Singh, Ran Vijay Kumar
A1 Raman, Ashok Kumar
A1 Anandasadagopan, Suresh Kumar
A1 Karuppanan, Parimala
A1 Venkatesan, Subramanian
A1 Sardana, Harish Kumar
A1 Kothari, Anamika
A1 Jain, Rishabh
A1 Thakur, Anupma
A1 Parihar, Devendra Singh
A1 Saifi, Anas
A1 Kaur, Jasleen
A1 Kumar, Virendra
A1 Mishra, Avinash
A1 Goger, Iranna
A1 Rayasam, Geethavani
A1 Singh, Praveen
A1 Chakraborty, Rahul
A1 Chaturvedi, Gaura
A1 Karunakar, Pinreddy
A1 Yadav, Rohit
A1 Singhmar, Sunanda
A1 Singh, Dayanidhi
A1 Sarkar, Sharmistha
A1 Bhattacharya, Purbasha
A1 Acharya, Sundaram
A1 Singh, Vandana
A1 Verma, Shweta
A1 Soni, Drishti
A1 Seth, Surabhi
A1 Vashisht, Shakshi
A1 Thakran, Sarita
A1 Fatima, Firdaus
A1 Singh, Akash Pratap
A1 Sharma, Akanksha
A1 Sharma, Babita
A1 Subramanian, Manikandan
A1 Padwad, Yogendra
A1 Hallan, Vipin
A1 Patial, Vikram
A1 Singh, Damanpreet
A1 Tirpude, Narendra Vijay
A1 Chakrabarti, Partha
A1 Maity, Sujay Krishna
A1 Ganguly, Dipyaman
A1 Sarkar, Jit
A1 Ramakrishna, Sistla
A1 Kumar, Balthu Narender
A1 Kumar, A Kiran
A1 Gandhi, Sumit G.
A1 Jamwal, Piyush Singh
A1 Chouhan, Rekha
A1 Jamwal, Vijay Lakshmi
A1 Kapoor, Nitika
A1 Ghosh, Debashish
A1 Thakkar, Ghanshyam
A1 Subudhi, Umakanta
A1 Sen, Pradip
A1 Chaudhury, Saumya Ray
A1 Kumar, Rashmi
A1 Gupta, Pawan
A1 Tuli, Amit
A1 Sharma, Deepak
A1 Ringe, Rajesh P.
A1 D, Amarnarayan
A1 Kulkarni, Mahesh
A1 Shanmugam, Dhanasekaran
A1 Dharne, Mahesh S
A1 Dastager, Syed G.
A1 Joshi, Rakesh
A1 Patil, Amita P.
A1 Mahajan, Sachin N.
A1 Khan, Abu Junaid
A1 Wagh, Vasudev
A1 Yadav, Rakeshkumar
A1 Khilari, Ajinkya
A1 Bhadange, Mayuri
A1 Chaurasiya, Arvindkumar H.
A1 Kulsange, Shabda E
A1 Khairnar, Krishna
A1 Paranjape, Shilpa
A1 Kalita, Jatin
A1 Sastry, G. Narahari
A1 Phukan, Tridip
A1 Manna, Prasenjit
A1 Romi, Wahengbam
A1 Bharali, Pankaj
A1 Ozah, Dibyajyoti
A1 Sahu, Ravi Kumar
A1 Babu, Elapavalooru V.S.S.K.
A1 Sukumaran, Rajeev
A1 Nair, Aiswarya R
A1 Kooloth-Valappil, Prajeesh
A1 Puthiyamadam, Anoop
A1 Velayudhanpillai, Adarsh
A1 Chodankar, Kalpana
A1 Damare, Samir
A1 Madhavi, Yennapu
A1 Aggarwal, Ved Varun
A1 Dahiya, Sumit
A1 Agrawal, Anurag
A1 Dash, Debasis
A1 Sengupta, Shantanu
YR 2021
UL http://medrxiv.org/content/early/2021/02/28/2021.01.12.21249713.abstract
AB To understand the spread of SARS-CoV2, in August and September 2020, the Council of Scientific and Industrial Research (India), conducted a sero-survey across its constituent laboratories and centers across India. Of 10,427 volunteers, 1058 (10.14%) tested positive for SARS CoV2 anti-nucleocapsid (anti-NC) antibodies; 95% with surrogate neutralization activity. Three-fourth recalled no symptoms. Repeat serology tests at 3 (n=346) and 6 (n=35) months confirmed stability of antibody response and neutralization potential. Local sero-positivity was higher in densely populated cities and was inversely correlated with a 30 day change in regional test positivity rates (TPR). Regional seropositivity above 10% was associated with declining TPR. Personal factors associated with higher odds of sero-positivity were high-exposure work (Odds Ratio, 95% CI, p value; 2·23, 1·92–2·59, 6·5E-26), use of public transport (1·79, 1·43–2·24, 2·8E-06), not smoking (1·52, 1·16–1·99, 0·02), non-vegetarian diet (1·67, 1·41–1·99, 3·0E-08), and B blood group (1·36,1·15-1·61, 0·001).Impact Statement Widespread asymptomatic and undetected SARS-CoV2 infection affected more than a 100 million Indians by September 2020. Declining new cases thereafter may be due to persisting humoral immunity amongst sub-communities with high exposure.Funding Council of Scientific and Industrial Research, India (CSIR)Competing Interest StatementThe authors have declared no competing interest.Funding StatementCouncil of Scientific and Industrial Research, India (CSIR) The sponsor of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CSIR IGIB: Institutional Ethical CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified categorized data of the participants can be provided on request basis after approval of ethics committee of the institute/organisation to which the requesting person belongs, stating the potential need and usage and signing of an agreement with the corresponding authors on behalf of CSIR IGIB. The request could be made to the corresponding authors after 90 days of publication.